Clinical Trials Sponsored by Dragonfly Research, LLC

Total 1851 results

Dragonfly Research, LLC

Completed

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab (OCR-VAX)

Pathologic Processes | Nervous System Diseases | Immune System Diseases | Multiple Sclerosis | Demyelinating Autoimmune Diseases, CNS | Autoimmune Diseases of the Nervous System | Demyelinating Diseases | Autoimmune Diseases

United States
Derm Research, PLLC
WFH MEDICAL, LLC

Completed

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Acne Vulgaris

United States
Pharmtechnology LLC
Ligand Research, LLC

Completed

Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
Ligand Research, LLC

Completed

Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
4Life Research, LLC

Completed

Clinical Study to Assess a Dietary Supplement on Sleep Health and Quality

Sleep Quality | Sleep Health

United States
Research Insight LLC

Completed

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study (CLEAR)

Dry Eye

United States
Research Insight LLC

Completed

Veracity Surgical: A Time/Motion and Quality of Care Study

Cataract

United States
Research Insight LLC

Completed

The PanOptix Trifocal IOL: A Study of Patient Satisfaction, Visual Disturbances, and Uncorrected Visual Performance

Cataract Surgery

United States
Uro-Research, LLC

Unknown

Tissue Bonding Cystostomy(TBC) (TBC)

Urinary Incontinence | Spinal Cord Injury (SCI) | Chronic Urinary Retention
4Life Research, LLC

Completed

Salivary Immunoglobulin A (sIgA) Normal Range Study (sIgA)

Salivary Immunity

United States
Puer Research, LLC

Enrolling by invitation

PUER ("Previously Unrecognized Emerging Risks") Life Clinical Study (PUER)

Aging

United States
Research Insight LLC

Completed

The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction

Cataract

United States
Research Insight LLC

Completed

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization (CLEAN)

Dry Eye

United States
Research Insight LLC

Completed

Evaluation of the Accuracy & Safety of the LaserArcs Nomogram

Cataract | Astigmatism

United States
Research Center, LLC

Completed

Clinical Evaluation of Effectiveness and Safety of Dietary Supplement Potensa in Men With Erectile Dysfunction

Erectile Dysfunction

Russian Federation
Medicus Research, LLC

Completed

MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge

Nasal Breathing
Genesis Research LLC

Recruiting

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

Prostate Cancer | Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen

United States
4Life Research, LLC

Completed

Clinical Study to Evaluate the Impact of aKwa Skincare System on Skin Health

Sin Health | Skin Hydration | Skin Wrinkles | Skin Porphyrins | Facial Skin Red Spots | Facial Skin Red Vasculature

United States
Research Insight LLC

Completed

The DEPOT Study (Dry Eye Prescription Options for Therapy)

Dry Eye

United States
4Life Research, LLC

Completed

RiteStart Personal Nutritional Dietary Study (RESPOND)

Healthy Nutrition

United States
Research Insight LLC

Completed

Vivity Insight: A Study of Patient Satisfaction and Visual Performance

Cataract

United States
Research Insight LLC

Completed

Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

Dry Eye Syndromes

United States
Research Insight LLC

Completed

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

Cataract

United States
Research Insight LLC

Completed

Comparison of Pre-operative Measurements With Intraoperative Aberrometry in Predicting Correction for Low Toric Lens Correction in Cataract Surgery

Cataract Surgery

United States
Medicus Research, LLC

Completed

DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study

Eczema
Medicus Research, LLC

Completed

The Effects of the Onion-Pumpkin Extract on Blood Pressure

Blood Pressure
Obslap Research LLC

Completed

My Scrivener® - Measuring Effectiveness and Dose Response in Children

Stroke | Cerebral Palsy | ADHD | Traumatic Brain Injury | Dyslexia | Attention Deficit Disorder | Asperger's Syndrome

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Pharmtechnology LLC
X7 Clinical Research LLC

Completed

Bioequivalence Study of Two Formulations of Tablets Aceclofenac 100 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Terminated

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, France, Poland, United Kingdom, Germany, Taiwan, Spain, Bulgaria, Romania, Turkey, Ukraine, Canada, Korea, Republic of, Netherlands, Russian Federation, Belgium, Brazil, Hungary, Czechia, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | B Cell Lymphoma | Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Diffuse Well-differentiated Lymphocytic Lymphoma | B-Cell Diffuse Lymphoma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

Healthy Volunteer

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Healthy Volunteer

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, France, Poland, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Israel, Turkey, Ukraine, Japan, Canada, Greece, Korea, Republic of, Netherlands, Brazil, Russian Federation, Puerto Rico, Australia, I... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, Spain, Korea, Republic of, Australia, Austria, Canada, France, Germany, Israel, Italy, Netherlands, Russian Federation, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

United States, Spain, France, Canada, Germany, Italy, Australia, United Kingdom, Greece
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Taiwan, Malaysia, Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, Spain, Belgium, Germany, Russian Federation
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Mantle Cell Lymphoma

United States, France, United Kingdom, Belgium, Spain, Israel, Puerto Rico, Poland, Russian Federation

Clinical Trials Sponsored by Dragonfly Research, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations